Press Releases RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Market Closed - Hong Kong S.E. Other stock markets 03:59:31 2024-04-29 EDT			5-day change	1st Jan Change
28 ^HKD	-8.20%		-1.23%	-25.23%

04-26	RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-04	Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	01-24	AQ
Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors	23-07-09	PR
RemeGen Co., Ltd. - Expanded Access Policy for Investigational Product	23-06-06	AQ
RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name	23-06-05	PR
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis	22-10-12	PR
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China	22-09-20	AQ
RemeGen : ANNOUNCEMENT REGARDING H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE	21-05-17	PU
RemeGen : (1) PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE; (3) UNCOVERED DEFICIT OF THE COMPANY AMOUNTING TO ONE-THIRD OF THE TOTAL SHARE CAPITAL; (4) PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (5) NOTICE OF EGM AND CLASS MEETINGS	21-05-14	PU
RemeGen : NOTICE OF THE 2021 FIRST CLASS MEETING OF H SHAREHOLDERS	21-05-14	PU
RemeGen : PROXY FORM FOR USE AT THE 2021 FIRST CLASS MEETING OF H SHAREHOLDERS	21-05-14	PU
RemeGen : PROXY FORM FOR USE AT THE 2021 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS	21-05-14	PU
RemeGen : NOTICE OF THE 2021 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS	21-05-13	PU
RemeGen : NOTICE OF THE 2021 SECOND EXTRAORDINARY GENERAL MEETING	21-05-13	PU
RemeGen : PROXY FORM FOR USE AT THE 2021 SECOND EXTRAORDINARY GENERAL MEETING	21-05-13	PU
RemeGen : PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS AND PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE AND UNCOVERED DEFICIT OF THE COMPANY AMOUNTING TO ONE-THIRD OF THE TOTAL SHARE CAPITAL AND PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEE	21-05-10	PU
RemeGen : CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF ASSETS	21-05-03	PU
RemeGen : NOTICE OF 2020 ANNUAL GENERAL MEETING	21-04-28	PU
RemeGen : CLARIFICATION ANNOUNCEMENT RELATING TO THE 2020 RESULTS ANNOUNCEMENT	21-04-23	PU
RemeGen : CLOSURE OF REGISTER OF MEMBERS FOR 2020 ANNUAL GENERAL MEETING AND 2021 SECOND EXTRAORDINARY GENERAL MEETING	21-04-19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Press Releases

Filters